CoChat
Sign Up
Cited by 124Amyotrophic Lateral Sclerosis ResearchGenetic Neurodegenerative DiseasesAlzheimer's disease research and treatments

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients

Open access
Prudencio, Mercedes, Gonzales, Patrick K., Cook, Casey N., Gendron, Tania F., Daughrity, Lillian M., Song, Yuping, Ebbert, Mark T.W., van Blitterswijk, Marka, Zhang, Yong-Jie, Jansen-West, Karen, Baker, Matthew C., DeTure, Michael, Rademakers, Rosa, Boylan, Kevin B., Dickson, Dennis W., Petrucelli, Leonard, Link, Christopher D.·2017·Human Molecular Genetics
DOI 10.1093/hmg/ddx233PMC PMC5886204
Open this paper in CoChat — free accountOpen PDF

Abstract

Significant transcriptome alterations are detected in the brain of patients with amyotrophic lateral sclerosis (ALS), including carriers of the C9orf72 repeat expansion and C9orf72-negative sporadic cases. Recently, the expression of repetitive element transcripts has been associated with toxicity and, while increased repetitive element expression has been observed in several neurodegenerative diseases, little is known about their contribution to ALS. To assess whether aberrant expression of repetitive element sequences are observed in ALS, we analysed RNA sequencing data from C9orf72-positive and sporadic ALS cases, as well as healthy controls. Transcripts from multiple classes and subclasses of repetitive elements (LINEs, endogenous retroviruses, DNA transposons, simple repeats, etc.) were significantly increased in the frontal cortex of C9orf72 ALS patients. A large collection of patient samples, representing both C9orf72 positive and negative ALS, ALS/FTLD, and FTLD cases, was used to validate the levels of several repetitive element transcripts. These analyses confirmed that repetitive element expression was significantly increased in C9orf72-positive compared to C9orf72-negative or control cases. While previous studies suggest an important link between TDP-43 and repetitive element biology, our data indicate that TDP-43 pathology alone is insufficient to account for the observed changes in repetitive elements in ALS/FTLD. Instead, we found that repetitive element expression positively correlated with RNA polymerase II activity in postmortem brain, and pharmacologic modulation of RNA polymerase II activity altered repetitive element expression in vitro. We conclude that increased RNA polymerase II activity in ALS/FTLD may lead to increased repetitive element transcript expression, a novel pathological feature of ALS/FTLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/ddx233

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Repetitive element transcripts are enriched in the frontal cortex of c9ALS cases. Using RNAseq data from 9 healthy controls, 10 sALS and 8 c9ALS cases (17), we evaluated changes in the expression of repetitive elements. (A) MA plot showing the Log2 fold change and mean repetitive element expression levels in the human cortex tissue of c9ALS brains compared to sALS. Note the 300 significant changes are depicted in red (FDR < 0.1). (B) Main class distribution of the repetitive elements significantly altered in the frontal cortex of c9ALS vs. sALS cases.
Figure 1 Repetitive element transcripts are enriched in the frontal cortex of c9ALS cases. Using RNAseq data from 9 healthy controls, 10 sALS and 8 c9ALS cases (17), we evaluated changes in the expression of repetitive elements. (A) MA plot showing the Log2 fold change and mean repetitive element expression levels in the human cortex tissue of c9ALS brains compared to sALS. Note the 300 significant changes are depicted in red (FDR < 0.1). (B) Main class distribution of the repetitive elements significantly altered in the frontal cortex of c9ALS vs. sALS cases.CC BY-NC · PubMed Central
Figure 2 Increased repetitive element accumulation in the frontal cortex of c9ALS/FTLD cases. A series of repetitive elements identified to be upregulated in c9ALS vs. sALS cases in our RNAseq analyses were validated in a large cohort of cases (Supplementary Material, Table S1) by qRT-PCR: 56 C9+, 46 C9-, 9 healthy controls. Validations were done for elements belonging to LTR (A), SINE (B) and LINE (C) repetitive element classes. Note, three of the repetitive elements shown (LTR70, MER21B, AluYa5) did not reach statistical significance from the RNAseq data (FDR > 0.1) but we observed significant changes by qRT-PCR. Statistical analyses were performed to compare all groups using a One-way ANOVA followed by Dunn’s multiple comparison test, *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 2 Increased repetitive element accumulation in the frontal cortex of c9ALS/FTLD cases. A series of repetitive elements identified to be upregulated in c9ALS vs. sALS cases in our RNAseq analyses were validated in a large cohort of cases (Supplementary Material, Table S1) by qRT-PCR: 56 C9+, 46 C9-, 9 healthy controls. Validations were done for elements belonging to LTR (A), SINE (B) and LINE (C) repetitive element classes. Note, three of the repetitive elements shown (LTR70, MER21B, AluYa5) did not reach statistical significance from the RNAseq data (FDR > 0.1) but we observed significant changes by qRT-PCR. Statistical analyses were performed to compare all groups using a One-way ANOVA followed by Dunn’s multiple comparison test, *P < 0.05, **P < 0.01, ***P < 0.001.CC BY-NC · PubMed Central
Figure 3 Inhibition of CDK9 leads to a decrease in RNApol II activity and repetitive element expression. HEK293T cells were treated with DMSO control and the indicated amounts of LDC000067, a CDK9 inhibitor, for a total of 3 h. (A) Immunoblots showing the levels of phosphorylated RNApol II largest subunit (pRPB1), total RPB1 and GAPDH, in response to different doses of CDK9 inhibitor. (B) Quantification of immunoblots from 2 independent experiments in which each condition was performed in duplicates, and in which pRPB1 and total RPB1 protein levels were normalized to GAPDH or as pRPB1/Total RPB1 ratio. (C, D) qRT-PCR analyses show a significant response to CDK9 inhibition of repetitive elements belonging to the LTR (C) and SINE (D) classes. Statistical analyses were performed to compare all groups using a One-way ANOVA followed by Bonforreoni’s multiple comparison test, *P < 0.05, **P < 0.01, #P < 0.0001.
Figure 3 Inhibition of CDK9 leads to a decrease in RNApol II activity and repetitive element expression. HEK293T cells were treated with DMSO control and the indicated amounts of LDC000067, a CDK9 inhibitor, for a total of 3 h. (A) Immunoblots showing the levels of phosphorylated RNApol II largest subunit (pRPB1), total RPB1 and GAPDH, in response to different doses of CDK9 inhibitor. (B) Quantification of immunoblots from 2 independent experiments in which each condition was performed in duplicates, and in which pRPB1 and total RPB1 protein levels were normalized to GAPDH or as pRPB1/Total RPB1 ratio. (C, D) qRT-PCR analyses show a significant response to CDK9 inhibition of repetitive elements belonging to the LTR (C) and SINE (D) classes. Statistical analyses were performed to compare all groups using a One-way ANOVA followed by Bonforreoni’s multiple comparison test, *P < 0.05, **P < 0.01, #P < 0.0001.CC BY-NC · PubMed Central
Figure 4 CDK9 and SUPT4H RNA levels are elevated in C9orf72-positive cases. The levels of CDK9 (A) and SUPT4H1 (B) RNA were assessed by qRT-PCR as described in methods for our large cohort of cases (Supplementary Material, Table S1). Statistical analyses were performed to compare all groups using a One-way ANOVA followed by Dunn’s multiple comparison test, **P < 0.01, ***P < 0.001. Of note, results from a subsequent linear regression model were also significant (C9+ vs. C9-: SUPT4H, P = 0.0288; CDK9, P = 0.0059), while correcting for disease duration, disease subtype, and age at death.
Figure 4 CDK9 and SUPT4H RNA levels are elevated in C9orf72-positive cases. The levels of CDK9 (A) and SUPT4H1 (B) RNA were assessed by qRT-PCR as described in methods for our large cohort of cases (Supplementary Material, Table S1). Statistical analyses were performed to compare all groups using a One-way ANOVA followed by Dunn’s multiple comparison test, **P < 0.01, ***P < 0.001. Of note, results from a subsequent linear regression model were also significant (C9+ vs. C9-: SUPT4H, P = 0.0288; CDK9, P = 0.0059), while correcting for disease duration, disease subtype, and age at death.CC BY-NC · PubMed Central
Figure 5 The levels of phosphorylated RPB1 protein are elevated in C9orf72-positive cases. The levels of phosphorylated RPB1 (pRPB1, (A) and total RPB1 (B) proteins were assessed by immunoblotting as described in methods for our large cohort of cases (Supplementary Material, Table S1) and normalized to GAPDH protein levels. Note the levels of pRPB1 are also presented normalized to total RPB1 levels (C). Statistical analyses were performed to compare all groups using a One-way ANOVA followed by Dunn’s multiple comparison test, *P < 0.05.
Figure 5 The levels of phosphorylated RPB1 protein are elevated in C9orf72-positive cases. The levels of phosphorylated RPB1 (pRPB1, (A) and total RPB1 (B) proteins were assessed by immunoblotting as described in methods for our large cohort of cases (Supplementary Material, Table S1) and normalized to GAPDH protein levels. Note the levels of pRPB1 are also presented normalized to total RPB1 levels (C). Statistical analyses were performed to compare all groups using a One-way ANOVA followed by Dunn’s multiple comparison test, *P < 0.05.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Prudencio, M., Gonzales, P. K., Cook, C. N., Gendron, T. F., Daughrity, L. M., Song, Y., Ebbert, M. T. W., van Blitterswijk, M., Zhang, Y.-J., Jansen-West, K., Baker, M. C., DeTure, M., Rademakers, R., Boylan, K. B., Dickson, D. W., Petrucelli, L., & Link, C. D.
Affiliations
  • Mayo Clinic (US)
  • Integrative Physiology, Institute for Behavioral Genetics University of Colorado, CO 80309, USA
  • Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
  • Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA
Corresponding author
Petrucelli, Leonard
ORCID
Venue
Human Molecular Genetics
Publisher
Oxford University Press (OUP)
Published
2017-06-16
Volume
26
Issue
17
Pages
3421-3431
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
DOI
10.1093/hmg/ddx233
PMC
PMC5886204
OpenAlex
W2626250818
Cited by
122
References
54
Citations by year
2026: 12 · 2025: 14 · 2024: 11 · 2023: 14 · 2022: 13 · 2021: 13 · 2020: 11 · 2019: 18 · 2018: 13 · 2017: 3
FWCI
8.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Human Molecular Genetics (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • NIH
  • National Institute of Neurological Disorders and Stroke
  • NINDS (R01NS063964, R21NS089979, R35NS097273, R21NS084528, P01NS084974, P01NS099114, R01NS088689, R01NS093865, R35NS097261, R01NS080882)
  • Department of Defense (AL130125)
  • Amyotrophic Lateral Sclerosis Association
  • Association for Frontotemporal Degeneration
  • Muscular Dystrophy Association (#416137)
  • National Center for Advancing Translational Sciences
  • NCATS
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
amyotrophic lateral sclerosis, frontotemporal lobar degeneration, C9orf72 repeat expansion, TDP-43, lines, endogenous retroviruses, DNA transposons, simple repeats, frontal cortex, neurodegeneration, pharmacological modulation
MeSH terms
C9orf72 Protein, Aged, Amyotrophic Lateral Sclerosis, Autopsy, Brain, Female, Frontal Lobe, Heterozygote, Humans, Male, Middle Aged, Mutation, Repetitive Sequences, Nucleic Acid, RNA Polymerase II, Transcriptional Activation, Case-Control Studies, Sequence Analysis, RNA, Neurodegenerative Diseases, DNA Repeat Expansion, Frontotemporal Lobar Degeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review